AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01996917 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Prineo
Description: After a Wise pattern breast reduction, one breast will have final layer closure with Prineo, while the other breast will be closed in the standard fashion with sutures.
Study NCT05865938 — intervention group
Intervention type: DEVICE
Intervention: PASCAL vs. MitraClip
Description: transcatheter mitral valve repair of the mitral valve (M-TEER) using the Edwards PASCAL Transcatheter Valve Repair System or the Abbott MitraClip in patients with severe and symptomatic degenerative or functional mitral regurgitation (FMR).~The type of device system used was not randomized but was determined by the operational structuring of the mitral valve program such that patients were scheduled for the next available implantation date with weekly alternating time slots for MitraClip device and PASCAL device.
Study NCT03806348 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resuturing
Description: Early reconstruction of the perineal body after wound dehiscence within two weeks of delivery.
Study NCT02993588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: Melatonin 6 mg tablet once daily
Study NCT02993588 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: one tablet once daily
Study NCT01884441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Schedule:~Day 2: Bendamustine 90mg/mq Day 3: Bendamustine 90mg/mq for a maximum of 4 cycles
Study NCT01884441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Day 1: Gemcitabine 800mg/mq, Day 4: Gemcitabine 800mg/mq for a maximum of 4 cycles
Study NCT01884441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: Day 1 Vinorelbine 20mg/mq for a maximum of 4 cycles
Study NCT01052246 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fixed combination of clindamycin 1% + benzoyl peroxide 5%
Description: Topical monotherapy with a fixed combination of 1% clindamycin and 5% benzoyl peroxide hydrating gel (Duac® Akne Gel, Stiefel Laboratorium GmbH, Offenbach, Germany). In order to provide standardized condition within the sample, the gel was applied on the whole face regardless of the lesion location. The gel was applied once per day in the evening throughout the observation period and left in place overnight.
Study NCT01052246 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulsed dye laser
Description: Patients randomized in the experimental group received two additional treatments with a pulsed dye laser using the following parameters:~* Wavelength 585 nm~* Energy fluence 3 J/cm2~* Pulse duration 0.35 msec~* Spot size 7 mm
Study NCT02492048 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cellutome Epidermal Harvesting System
Description: Cellutome Epidermal Harvesting System
Study NCT02492048 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Split Thickness Skin Graft
Description: Split Thickness Skin Graft
Study NCT00986466 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: exercise and vitamin D supplementation
Description: 20 µg (800 IU) of vitamin D per day for two years supervised training two times a week for 12 months, and once a week during the next 12 months
Study NCT00986466 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: exercise and vitamin D supplementation
Description: placebo per day for two years supervised training two times a week for 12 months, and once a week during the next 12 months
Study NCT00986466 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: exercise and vitamin D supplementation
Description: 20 µg (800 IU) of vitamin D per day for two years no supervised training (maintenance of their current level of physical activity)
Study NCT00986466 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: exercise and vitamin D supplementation
Description: placebo per day for two years no supervised training (maintenance of their current level of physical activity)
Study NCT02511613 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Squalamine Lactate Ophthalmic Solution, 0.2%
Description: Squalamine Lactate Ophthalmic Solution, 0.2% administered BID
Study NCT02511613 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Ophthalmic Solution
Description: Placebo Ophthalmic Solution, administered BID
Study NCT02511613 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ranibizumab
Description: ranibizumab intravitreal injection
Study NCT02511613 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ranibizumab
Description: ranibizumab intravitreal injection
Study NCT00566527 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ProQuad® manufactured with recombinant Human Albumin (rHA)
Description: A 2-dose regimen of ProQuad® (0.5 mL per dose) given via subcutaneous injection into the deltoid muscle at a 3-month interval. Each dose contains measles virus Enders' Edmonston strain (live attenuated), mumps virus Jeryl Lynn™ (Level B) strain (live attenuated), rubella virus Wistar RA 27 or 3 strain (live attenuated), and varicella virus Oka or Merck strain (live attenuated).
Study NCT02354911 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immunoregulatory Dendritic Cells
Description: Autologous dendritic cells harvested by leukapheresis and engineered ex vivo via incubation with antisense DNA oligonucleotides targeting the primary transcripts of CD40, CD80 and CD86. The ex vivo engineered product is then administered via blinded intradermal injection in the peri-umbilical region of the abdomen given as 4 separate injections at 2-week intervals (\~10 million cells/injection).
Study NCT02354911 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator: Placebo Control
Description: Blinded intradermal injections in the peri-umbical region of the abdomen given as 4 separate injections at 2-week intervals
Study NCT02334241 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sorbact®
Description: Sorbact® is available in many types and sizes. These different presentations are available allowing management of quite all types of wounds of various anatomical locations, sizes or depths. Application of any of these presentations is allowed and may change during study course according to wound evolution.
Study NCT02334241 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Best local cares
Description: Participating centers will provide a list of dressings they planned to use in the best local cares arm. This list must be validated by the study Steering Committee members
Study NCT03083977 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Safe and Sound Protocol
Description: The intervention features music processed based on the resonating frequencies of the middle ear
Study NCT01279252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metronidazole, clarithromycin, ciprofloxacin and lansoprazole
Study NCT04528888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Description: Enoxaparin will be administered subcutaneously at standard prophylactic dose (i.e., 4000 UI once day, increased to 6000 UI once day for patients weighting more than 90 kg). The treatment will be administered daily up to ICU discharge. After ICU discharge it may be continued or interrupted in the destination ward up to clinical judgement of the attending physician.
Study NCT04528888 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: Enoxaparin will be administered subcutaneously at standard prophylactic dose (i.e., 4000 UI once day, increased to 6000 UI once day for patients weighting more than 90 kg). The treatment will be administered daily up to ICU discharge. After ICU discharge it may be continued or interrupted in the destination ward up to clinical judgement of the attending physician.
Study NCT04528888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Methylprednisolone will be administered intravenously with an initial bolus of 0,5 mg/kg followed by administration of 0,5 mg/kg 4 times daily for 7 days, 0,5 mg/kg 3 times daily from day 8 to day 10, 0,5 mg/kg 2 times daily at days 11 and 12 and 0,5 mg/kg once daily at days 13 and 14.
Study NCT04528888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: unfractionated heparin
Description: Patients in this group will receive unfractionated heparin and methylprednisolone. Unfractionated heparin will be administered intravenously at therapeutic doses. The infusion will be started at an infusion rate of 18 IU/kg/hour and then modified to attain APTT Ratio in the range 1.5-2.0. aPTT will be periodically checked at intervals no longer than 12 hours. The treatment with unfractionated heparin will be administered up to ICU discharge. After ICU discharge anticoagulant therapy may be interrupted or switched to prophylaxis with LMWH in the destination ward up to clinical judgement of the attending physician.
Study NCT00933283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telaprevir
Description: Telaprevir 750 mg will be administered orally, every 8 hours from Day 1 to Day 7, along with methadone, once daily.
Study NCT00933283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone
Description: Methadone 30 to 130 mg will be administered as a stable oral therapy from Day -14 to Day -1, in combination with telaprevir from Day 1 to Day 7, and then alone as a continued intake dose for an additional 30 to 32 days.
Study NCT01574664 — intervention group
Intervention type: DEVICE
Intervention: RFID Tag (Health Beacon)
Description: The radiologist or surgeon will place the Health Beacons RFID Tag under ultrasonic or stereotactic guidance. The surgeon will use the Tagfinder to locate the lesion.
Study NCT04372290 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product A
Description: Usual brand (UB) filtered, combustible cigarette
Study NCT00557193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT00557193 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Given IV
Study NCT00557193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV or IT
Study NCT00557193 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Description: Given IV or IT
Study NCT00557193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin Hydrochloride
Description: Given IV
Study NCT00557193 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daunorubicin Hydrochloride
Description: Given IV
Study NCT00557193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given IV or PO
Study NCT00557193 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Given IV or PO
Study NCT00557193 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO
Study NCT00557193 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Echocardiography
Description: Undergo ECHO
Study NCT00557193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV
Study NCT00557193 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: Given IV
Study NCT00557193 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given IV or SC
Study NCT00557193 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Filgrastim
Description: Given IV or SC
Study NCT00557193 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00557193 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00557193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lestaurtinib
Description: Given PO
Study NCT00557193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: Given IV
Study NCT00557193 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin Calcium
Description: Given IV
Study NCT00557193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mercaptopurine
Description: Given PO
Study NCT00557193 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mercaptopurine
Description: Given PO
Study NCT00557193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IV, IT, or PO
Study NCT00557193 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Given IV, IT, or PO
Study NCT00557193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Given IV
Study NCT00557193 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: Given IV
Study NCT00557193 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA
Study NCT00557193 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA
Study NCT00557193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase
Description: Given IM
Study NCT00557193 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegaspargase
Description: Given IM
Study NCT00557193 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT00557193 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT00557193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO
Study NCT00557193 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Given PO
Study NCT00557193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Therapeutic Hydrocortisone
Description: Given IT
Study NCT00557193 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic Hydrocortisone
Description: Given IT
Study NCT00557193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV
Study NCT00557193 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine Sulfate
Description: Given IV
Study NCT00906061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine and Docetaxel
Description: Docetaxel 50 mg/m2, IV, and Gemcitabine 2000 mg/m2, IV, on day 1 and 14 of each 28 day cycle. Number of Cycles: 6
Study NCT00000395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Study NCT00000395 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Folinic acid
Study NCT00000395 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Folic acid
Study NCT00566527 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ProQuad® manufactured with recombinant Human Albumin (rHA)
Description: A 2-dose regimen of ProQuad® (0.5 mL per dose) given via subcutaneous injection into the deltoid muscle at a 3-month interval. Each dose contains measles virus Enders' Edmonston strain (live attenuated), mumps virus Jeryl Lynn™ (Level B) strain (live attenuated), rubella virus Wistar RA 27 or 3 strain (live attenuated), and varicella virus Oka or Merck strain (live attenuated).
Study NCT00959946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosutinib
Description: Doses in part 1 include bosutinib 200 mg QD; bosutinib 300 mg QD. Depending on safety bosutinib can be administered at 200 mg/m2 QD. The MTD of the combination treatment determined from part 1, will be administered in part 2 (phase 2).
Study NCT00959946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Doses in part 1 include capecitabine 750 mg/m2 BID on days 1-14; capecitabine 625 mg/m2 BID on days 1-14. Depending on safety, capecitabine can also be administered at 1000 mg/m2 BID. The MTD of the combination treatment determined from part 1, will be administered in part 2 (phase 2).
Study NCT03925558 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotics
Study NCT03925558 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00903227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Evohaler pMDI
Description: One puff of inhaled Fluticasone Evohaler pMDI 50 µg twice a day (Total FP dose 100 µg)
Study NCT00903227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 1 puff of inhaled Placebo twice a day
Study NCT00903227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Evohaler
Description: One puff of inhaled Fluticasone Evohaler 250µg twice a day (Total daily FP dose 500µg)
Study NCT00903227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo intranasal spray
Description: placebo intranasal spray 2 squirts each nostril once a day
Study NCT00903227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluticasone propionate (Flixonase®)
Description: intranasal fluticasone propionate (Flixonase®) 50ug 2 squirts
Study NCT02971488 — intervention group
Intervention type: OTHER
Intervention: Screening for HCV in PWID and Linkage-To-Care
Description: Screening, diagnosis and treatment of HCV in PWID, will be part of a harm reduction strategy.~Treatment of HCV infected PWID will be delivered in a multidisciplinary care setting with services to reduce the risk of reinfection and for management of the common social and psychiatric comorbidities in this population.
Study NCT06199323 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Routine rehabilitation training
Description: 1. Balance function training: Patients were instructed to achieve weight shift between the left and right sides of the balance bar in a standing position.~2. Walking function training: based on hip, knee, and ankle control training, patients were instructed to take steps training.~3. Core muscle strength training: Patients were instructed to maintain 3 minutes of training in Bridge-style movement.~4. Functional training of daily living: including training on dressing and undressing, independent eating, painting, and writing.~Routine rehabilitation training was performed 30-45 minutes/time, 1-2 times/day, 5-7 days/week.
Study NCT06199323 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Routine rehabilitation training
Description: 1. Balance function training: Patients were instructed to achieve weight shift between the left and right sides of the balance bar in a standing position.~2. Walking function training: based on hip, knee, and ankle control training, patients were instructed to take steps training.~3. Core muscle strength training: Patients were instructed to maintain 3 minutes of training in Bridge-style movement.~4. Functional training of daily living: including training on dressing and undressing, independent eating, painting, and writing.~Routine rehabilitation training was performed 30-45 minutes/time, 1-2 times/day, 5-7 days/week.
Study NCT06199323 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Swallowing rehabilitation training
Description: 1. Swallowing-related organ training: including movement training of lip, mandibular muscle, cheek, tongue muscle, soft palate, as well as exercises of vocal cord closure, laryngeal lifting and pharyngeal muscle training. 5-15 minutes/time, 1-2 times/day, 5-7 days/week.~2. Sensory stimulation training: With the self-made popsicle, medical staff slowly and gently stimulated the patient's cheek, palatoquadrate, soft palate, posterior pharyngeal wall, tongue surface and sublingual area repeatedly. 5-25 minutes/time, 1-3 times/day, 3-7 days/week.~3. Direct training: When the patient's swallowing function improves to a certain extent of which the safety of oral intake can be basically ensured, oral feeding training (direct training) can be attempted gradually.~4. Mendelsohn maneuver: During the Mendelsohn maneuver, the patient consciously prolonged the duration of the muscle contraction in the throat during swallowing.15-30 minutes/time, once per day, 5 days/week.
Study NCT06199323 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Swallowing rehabilitation training
Description: 1. Swallowing-related organ training: including movement training of lip, mandibular muscle, cheek, tongue muscle, soft palate, as well as exercises of vocal cord closure, laryngeal lifting and pharyngeal muscle training. 5-15 minutes/time, 1-2 times/day, 5-7 days/week.~2. Sensory stimulation training: With the self-made popsicle, medical staff slowly and gently stimulated the patient's cheek, palatoquadrate, soft palate, posterior pharyngeal wall, tongue surface and sublingual area repeatedly. 5-25 minutes/time, 1-3 times/day, 3-7 days/week.~3. Direct training: When the patient's swallowing function improves to a certain extent of which the safety of oral intake can be basically ensured, oral feeding training (direct training) can be attempted gradually.~4. Mendelsohn maneuver: During the Mendelsohn maneuver, the patient consciously prolonged the duration of the muscle contraction in the throat during swallowing.15-30 minutes/time, once per day, 5 days/week.